Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo

By Pienta K.J.   Naik H.   Lehr J.E.  

Urology, Vol. 48, Iss. 1, 1996-07 ,pp. : 164-170

Elsevier

Access to resources Recommend Favorite

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

By Dimopoulos M.A.   Panopoulos C.   Bamia C.   Deliveliotis C.   Alivizatos G.   Pantazopoulos D.   Constantinidis C.   Kostakopoulos A.   Kastriotis I.   Zervas A.   Aravantinos G.   Dimopoulos C.  

Urology, Vol. 50, Iss. 5, 1997-11 ,pp. : 754-758

Elsevier

Access to resources Recommend Favorite

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer

By Hussain M.   Smith D.C.   El-Rayes B.F.   Du W.   Vaishampayan U.   Fontana J.   Sakr W.   Wood D.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 774-780

Elsevier

Access to resources Recommend Favorite